Year: 2019

A panel of experts to the U.S. FDA on Thursday recommended allowing Amarin Corp Plc’s fish-oil derived drug to be used as add-on therapy for reducing the chance of heart attacks and strokes in high-risk patients with cardiovascular disease. The panel voted 16-0 in favor of expanding approval, potentially opening up a multi-billion dollar opportunity for the company which has only one drug, Vascepa, in the market. Vascepa, a highly purified omega-3 fatty acid derived from fish oil, won U.S. approval in 2012 to lower high levels of triglycerides — a type of blood fat that can increase …read more […]

The U.S. Food and Drug Administration on Thursday approved BeiGene Ltd’s lymphoma treatment, validating the China-based drugmaker’s strategy of largely using data from trials held outside the United States to file for approval. The company tested the treatment, Brukinsa, in 118 patients with mantle cell lymphoma enrolled in two studies. About three-quarters were Asian, 21% Caucasian, and between 10% to 15% were from the United States, BeiGene said. …read more […]

Firm of the great Ray Dalio buys Taiwan-focused ETF Continue reading… …read more […]

The U.S. budget deficit jumped 34% in October compared to last year, and it’s on pace to top $1 trillion. Federal reserve chair Jerome Powell testifying for the second day on the Hill, warning that the ballooning debt could hamper fiscal policy during economic downturn.. but he said the day of reckoning is still further out. Dan Deming, KKM Financial’s Managing Director joins Yahoo Finance’s Akiko Fujita on The Ticker. …read more […]

I love trading long-term equity anticipation securities (LEAPS)…
LEAPS are long-term options that have at least one year left before expiration. Since they are more expensive than short-term options (because of the extra time value), many people avoid them.
However, as a fundamental tactician, my goal is not always short-term gains…
Even though most of my trades, LEAPS included, are held for a very short time period.
Confused?
Let me explain…
Because LEAPS have a lot of time on them, a short-term move in underlying shares is magnified in a LEAPS option.
Think about it…
The options pricing model has several components, and a change in any one …read more […]

Cisco shares tumbled after the tech conglomerate provided disappointing guidance for it’s fiscal second-quarter. Yahoo Finance’s Dan Howley joins Akiko Fujita on The Ticker to discuss why the stock is down despite earnings beating Wall Street’s estimates. …read more […]